• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

作者信息

Tachihara Motoko, Nishimura Yoshihiro

机构信息

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

J Thorac Dis. 2019 May;11(Suppl 9):S1289-S1291. doi: 10.21037/jtd.2019.04.76.

DOI:10.21037/jtd.2019.04.76
PMID:31245112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6560586/
Abstract
摘要

相似文献

1
Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.在接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者中，谁会患上超进展性疾病。
J Thorac Dis. 2019 May;11(Suppl 9):S1289-S1291. doi: 10.21037/jtd.2019.04.76.
2
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
3
Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.帕博利珠单抗治疗肺腺癌后出现的超进展性疾病：一例尸检病例研究
Respir Med Case Rep. 2019 Jun 13;28:100885. doi: 10.1016/j.rmcr.2019.100885. eCollection 2019.
4
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
5
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
6
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
7
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.抗PD-1（程序性细胞死亡蛋白1）/PD-L1（程序性死亡配体1）治疗期间的超进展性疾病：一项系统评价和荟萃分析。
Cancers (Basel). 2019 Nov 1;11(11):1699. doi: 10.3390/cancers11111699.
8
[Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].[晚期非小细胞肺癌患者外周血中PD-1和PD-L1的表达及其意义]
Zhonghua Yi Xue Za Zhi. 2019 Jan 8;99(2):111-114. doi: 10.3760/cma.j.issn.0376-2491.2019.02.007.
9
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.PD-1/PD-L1 抑制剂治疗晚期非小细胞肺癌患者的疗效：一项随机临床试验的荟萃分析。
Thorac Cancer. 2019 May;10(5):1176-1181. doi: 10.1111/1759-7714.13060. Epub 2019 Apr 10.
10
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.

引用本文的文献

1
Prognostic value of PD-1, PD-L1 and P53 in patients with non-small cell lung cancer after postoperative adjuvant chemoradiotherapy.PD-1、PD-L1和P53在非小细胞肺癌患者术后辅助放化疗后的预后价值
Am J Transl Res. 2022 Jul 15;14(7):4709-4718. eCollection 2022.
2
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.评估纳武利尤单抗联合或不联合伊匹单抗与安慰剂在 III 期随机对照试验中的 hyperprogression 与疾病自然进展的情况。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004273.
3
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.肌肉减少症和高 NLR 与二线帕博利珠单抗治疗非小细胞肺癌患者后发生超进展性疾病有关。
Clin Exp Immunol. 2020 Dec;202(3):353-362. doi: 10.1111/cei.13505. Epub 2020 Aug 26.
4
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.免疫治疗的黑色素瘤患者早期反应评估中PET体积参数的预后价值
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2787-2795. doi: 10.1007/s00259-020-04792-0. Epub 2020 Apr 15.

本文引用的文献

1
Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.基线肿瘤大小作为非小细胞肺癌免疫检查点抑制剂治疗的预测和预后因素
Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180.
2
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
3
Pseudoprogression and hyperprogression after checkpoint blockade.免疫检查点抑制剂治疗后的假性进展和超进展。
Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23.
4
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.抗 PD-1/PD-L1 治疗复发性和/或转移性头颈部鳞状细胞癌患者中的超进展。
Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.
5
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.T细胞活力与肿瘤负荷之比与抗PD-1反应相关。
Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.
6
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.免疫治疗后的超进展者：与加速生长率相关的基因组改变分析。
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.
7
A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment.一例接受纳武单抗治疗后可能出现“疾病复发”的非小细胞肺癌病例。
Case Rep Oncol Med. 2016;2016:1075641. doi: 10.1155/2016/1075641. Epub 2016 Dec 27.
8
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.纳武单抗治疗非小细胞肺癌患者假性进展2例报告——包括1例肿瘤消退后的组织学分析
Lung Cancer. 2016 Dec;102:44-48. doi: 10.1016/j.lungcan.2016.10.014. Epub 2016 Oct 29.
9
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
10
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.